MX2019012876A - Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina. - Google Patents

Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.

Info

Publication number
MX2019012876A
MX2019012876A MX2019012876A MX2019012876A MX2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A
Authority
MX
Mexico
Prior art keywords
cysteine engineered
domain containing
cysteine
binding molecules
type iii
Prior art date
Application number
MX2019012876A
Other languages
English (en)
Inventor
GOLDBERG Shalom
Lin Tricia
Jacobs Steven
O´Neil Karyn
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2019012876A publication Critical patent/MX2019012876A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Las moleculas monoespecificas y biespecificas que contienen dominios de FN3 de EGFR y/o c-Met modificados con cisteina que comprenden uno o más aminoacidos de cisteina libre se preparan por mutagenesis de una secuencia de ácido nucleico de una molecula parental y al reemplazar uno o más residuos de aminoacidos por cisteina para codificar las moléculas monoespecificas o biespecificas que contienen el dominio de FN3 modificado con cisteina; expresar las moleculas que contienen dominios de FN3 modificados con cisteina; y recuperar la molecula que contiene dominios de FN3 modificados con cisteina; las moleculas monoespecificas y biespecificas aisladas que contienen dominios de FN3 modificados con cisteina pueden unirse covalentemente a una etiqueta de deteccion o a una porcion de farmaco y usarse terapeuticamente.
MX2019012876A 2013-10-14 2016-04-14 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina. MX2019012876A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361890539P 2013-10-14 2013-10-14

Publications (1)

Publication Number Publication Date
MX2019012876A true MX2019012876A (es) 2019-12-11

Family

ID=52809988

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004862A MX2016004862A (es) 2013-10-14 2014-10-13 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.
MX2019012876A MX2019012876A (es) 2013-10-14 2016-04-14 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016004862A MX2016004862A (es) 2013-10-14 2014-10-13 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.

Country Status (12)

Country Link
US (3) US10196446B2 (es)
EP (1) EP3057608A4 (es)
JP (2) JP6585040B2 (es)
KR (2) KR20160067966A (es)
CN (1) CN105899226B (es)
AU (2) AU2014334627B2 (es)
BR (1) BR112016008125B1 (es)
CA (1) CA2926262A1 (es)
EA (1) EA035745B1 (es)
IL (1) IL244623B (es)
MX (2) MX2016004862A (es)
WO (1) WO2015057545A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20160067966A (ko) 2013-10-14 2016-06-14 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
US20190144503A1 (en) * 2016-04-27 2019-05-16 Regents Of The University Of Minnesota Methods for the identification of bifunctional compounds
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. CYSTEINE-MODIFIED TYPE III FIBRONECTIN BINDING MOLECULES
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3932432A1 (en) * 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
CN108743966B (zh) * 2018-04-24 2021-10-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108640982A (zh) * 2018-05-21 2018-10-12 华东师范大学 一种重组含双发色团光受体蛋白古紫质4及其构建方法和应用
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 Aro Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
CN115175691A (zh) * 2019-12-18 2022-10-11 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5846456A (en) 1996-01-17 1998-12-08 National Science Council Method of making gradient index optical element
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
DE60335000D1 (de) 2002-09-06 2010-12-30 Isogenica Ltd In vitro peptid-expressionsbank
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
RU2429014C2 (ru) * 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
EP2125896A2 (en) 2007-02-09 2009-12-02 Genetech, Inc. Anti-robo4 antibodies and uses therefor
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CA2710378A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
CN101965198A (zh) 2007-12-27 2011-02-02 诺瓦提斯公司 改进的基于纤连蛋白的结合分子及其用途
MX2010008874A (es) * 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
BRPI0906099A2 (pt) 2008-03-06 2015-07-21 Genentech Inc "método de tratamento do câncer em um indivíduo"
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
BRPI0913007A2 (pt) * 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CN102099373A (zh) 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
CA2726256C (en) 2008-05-30 2020-01-14 Genentech, Inc. Variant hhip1 protein and methods and uses thereof
AU2009300328A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
MX338038B (es) 2008-10-01 2016-03-30 Amgen Res Munich Gmbh Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
CA2757669A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
US8961977B2 (en) * 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
NZ602294A (en) 2010-03-10 2015-04-24 Genmab As Monoclonal antibodies against c-met
KR101747991B1 (ko) * 2010-04-13 2017-06-19 메디뮨 엘엘씨 Ｔｒａｉｌ ｒ2 특이적 다량체 스캐폴드
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
PL2571531T3 (pl) * 2010-04-30 2016-12-30 Kompozycje stabilizowanych domen fibronektyny, sposoby i zastosowania
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
WO2012162426A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
PT3447069T (pt) 2012-11-21 2020-11-13 Janssen Biotech Inc Anticorpos biespecíficos de egfr/c-met
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
KR20160067966A (ko) 2013-10-14 2016-06-14 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
US10925932B2 (en) 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains

Also Published As

Publication number Publication date
WO2015057545A3 (en) 2015-06-11
IL244623B (en) 2022-08-01
US10196446B2 (en) 2019-02-05
IL244623A0 (en) 2016-04-21
EA035745B1 (ru) 2020-08-05
US20150104808A1 (en) 2015-04-16
US11072663B2 (en) 2021-07-27
MX2016004862A (es) 2016-08-01
JP6585040B2 (ja) 2019-10-02
US11702475B2 (en) 2023-07-18
WO2015057545A2 (en) 2015-04-23
JP2017500003A (ja) 2017-01-05
CN105899226B (zh) 2020-05-12
KR20160067966A (ko) 2016-06-14
EP3057608A4 (en) 2017-10-11
EP3057608A2 (en) 2016-08-24
EA201690773A1 (ru) 2016-08-31
KR20220136463A (ko) 2022-10-07
CA2926262A1 (en) 2015-04-23
AU2019253863A1 (en) 2019-11-14
KR102478402B1 (ko) 2022-12-15
BR112016008125B1 (pt) 2023-11-21
AU2014334627B2 (en) 2019-07-25
CN105899226A (zh) 2016-08-24
AU2019253863B2 (en) 2022-03-10
US20210301025A1 (en) 2021-09-30
US20190263915A1 (en) 2019-08-29
AU2014334627A1 (en) 2016-04-07
JP2020011969A (ja) 2020-01-23
BR112016008125A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
MX2019012876A (es) Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.
MX2018016185A (es) Moléculas de unión al dominio de fibronectina tipo iii diseñadas de cisteína.
AR114031A2 (es) Moléculas de unión a 4-1bb
MY195318A (en) Multispecific Antibody Constructs
EP4270006A3 (en) General detection and isolation of specific cells by binding of labeled molecules
PH12015501651A1 (en) Antibody constructs for cdh19 and cd3
PH12015501672A1 (en) Binding molecules for bcma and cd3
WO2016040856A3 (en) Cysteine engineered antibodies and conjugates
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
EP2651411A4 (en) METHOD AND COMPOSITION FOR IMPROVED F-18 MARKING OF PROTEINS, PEPTIDES AND OTHER MOLECULES
GB2537077A (en) Methods for sequencing nucleic acids
AR104358A1 (es) Método para la purificación de proteínas
PH12015501687A1 (en) Novel binding proteins from pcsk9
GB201214580D0 (en) Benzocyanine compounds
IN2015DN00849A (es)
WO2011147762A3 (en) Stabilized radiopharmaceutical composition
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
PH12017500309A1 (en) Anti-vasa antibodies, and methods of production and use thereof
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
EP2554672A4 (en) NUCLEIC ACID STRUCTURE, METHOD FOR PRODUCING A COMPLEX AND SCREENING METHOD THEREFOR
WO2014058982A3 (en) Nuclear factor-erythroid 2 related factor 2 (nrf2) biosensors and modulators of nrf2
CY1117137T1 (el) 2-amino-3-methyl-hex-5-enoic acid και η χρηση του στην παραγωγη πεπτιδιων οπως bacitracins
CR20150249A (es) Móleculas de unión al dominio de fibronectina de tipo iii de egfr y c-met
AR097922A1 (es) Exotoxina a de pseudomonas modificada